Actually that's a topic near and dear to my heart, because my company is developing a novel steroid that for now can only be delivered IV, so we always have a raging debate about whether non-hospitalized patients would take the drug even if it's shown to be highly effective, given the burden of having to return to a medical facility daily for 5 to 10 days.
I'll be looking at all cause OPAT failure/adverse safety outcomes using my local VA's OPAT program over the past 3 years. Failure does include rehospitalization. I've done a bit of the lit review so far but everything points to greater satisfaction and reduced cost for outpatient over inpatient with similar efficacy rates. Infection control is a bit iffier, but there are ways to improve that too. There's definitely some of literature about location (home w/o services, home w/ services, SNF, dialysis centers, etc., And what people prefer. If you haven't, check out IDSA's latest OPAT guidance from late 2018, might be useful for your debates. If there's anything I can help with let me know! https://www.idsociety.org/practice-guideline/outpatient-antimicrobial-parenteral-therapy/